Document is current
Any future updates will be listed below
-
Authors
von Groote, Thilo
Bormann, Eike
Marcello, Matteo
Tunnicliffe, David J.
Göcze, Ivan
Sadjadi, Mahan
Forni, Lui G.
Gómez, Hernando
Kellum, John A.
Zarbock, Alexander https://orcid.org/0000-0002-2124-1714
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (493624047)
Deutsche Forschungsgemeinschaft (ZA 428/28-1)
Deutsche Forschungsgemeinschaft (ZA 428/29-1)
Deutsche Forschungsgemeinschaft (ZA 428/30-1)
Universitätsklinikum Münster
- License Information
-
More Information
Article History
Received: 20 November 2025
Accepted: 17 March 2026
First Online: 20 April 2026
Declarations
:
: TvG, EB, MM, DT, IG, MS have no potential conflict of interest to declare. AZ has received consulting fees from Astute-Biomerieux, Baxter, Bayer, Novartis, Guard Therapeutics, AM Pharma, Paion, Viatris, Dropshot, Fresenius, research funding from Astute-Biomerieux, Fresenius, Baxter, and speaker fees from Astute-Biomerieux, Fresenius, Baxter. LF received funding and honoraria from Baxter and consulting fees from AstraZeneca, Baxter, and SphingoTec. HG received consultancy fees for trilinear bio ventures, Novartis, and Talphera, speaker fees from bioMerieux and research grants from Baxter and biomMrieux. JAK holds royalties or licenses from CytoSorbents, and J3RM holds stock options of and is contracted by Spectral Medical and received honoraria from AstraZeneca, Bayer, Novartis, bioMéríeux, Mitsubishi Tenabe, and Chugai Pharma. AZ and JAK are named inventors on multiple patents (assigned to the Universities of Münster and Pittsburgh), involving TIMP-2 and IGFBP7, unrelated to the use of these biomarkers for AKI detection or risk stratification. Urinary TIMP-2 and IGFBP7 are measured in the commercially available NephroCheck assay marketed by bioMérieux; author relationships with Astute Medical/bioMérieux are disclosed above.
